Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass

Gynecologic Oncology

Volumn 139, Issue 2, 2015, Pages 248-252

  Lokich, Elizabeth ^a   Palisoul, Marguerite ^a,b   Romano, Nicole ^a   Craig Miller, M ^a   Robison, Katina ^a   Stuckey, Ashley ^a   Disilvestro, Paul ^a   Mathews, Cara ^a   Granai, C O ^a   Lambert Messerlian, Geralyn ^a   Moore, Richard G ^a  

^a BROWN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

HE4; Ovarian cyst; Pelvic mass; ROMA

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL OBSERVATION; COHORT ANALYSIS; CONSERVATIVE TREATMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; OVARY CARCINOMA; OVARY CYST; OVARY TUMOR; PATIENT REFERRAL; PELVIS TUMOR; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK OF OVARIAN MALIGNANCY ALGORITHM; SENSITIVITY AND SPECIFICITY; SURGICAL PATIENT; TUMOR DIFFERENTIATION; ALGORITHM; METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN CYSTS; OVARIAN NEOPLASMS; OVARIECTOMY; PROCEDURES; RISK ASSESSMENT; VERY ELDERLY; WATCHFUL WAITING; YOUNG ADULT;

CA 125 ANTIGEN; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOMARKERS, TUMOR; CA-125 ANTIGEN; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN CYSTS; OVARIAN NEOPLASMS; OVARIECTOMY; PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; WATCHFUL WAITING; YOUNG ADULT;

EID: 84952628450     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.09.010     Document Type: Article

References (27)

1. J.P. Curtin Management of the adnexal mass Gynecol. Oncol. 55 3 Pt 2 1994 Dec S42 S46
2. T. Pejovic, and F. Nezhat Laparoscopic management of adnexal masses the opportunities and the risks Ann. N. Y. Acad. Sci. 943 2001 Sep 255 268
3. National Institutes of Health Consensus Development Conference Statement Ovarian cancer: screening, treatment, and follow-up Gynecol. Oncol. 55 3 Pt 2 1994 Dec S4 14
4. S.S. Buys, E. Partridge, M.H. Greene, P.C. Prorok, D. Reding, T.L. Riley, and et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial Am. J. Obstet. Gynecol. 193 5 2005 Nov 1630 1639
5. J.L. Alcazar, G. Castillo, M. Jurado, and G.L. Garcia Is expectant management of sonographically benign adnexal cysts an option in selected asymptomatic premenopausal women? Hum. Reprod. 20 11 2005 Nov 3231 3234
6. I.J. Jacobs, S. Skates, A.P. Davies, R.P. Woolas, A. Jeyerajah, P. Weidemann, and et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study BMJ 313 7069 1996 Nov 30 1355 1358
7. T. Maggino, A. Gadducci, V. D'Addario, S. Pecorelli, A. Lissoni, M. Stella, and et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses Gynecol. Oncol. 54 2 1994 Aug 117 123
8. A.C.O.G. Practice Bulletin, number 83. Management of adnexal masses Obstet. Gynecol. 110 1 2007 Jul 201 214
9. Jacobs I, Bast RC, Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 1989 Jan;4(1):1-12.
10. R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.J. Allard, T. Verch, and et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol. Oncol. 108 2007 Nov 30 402 408
11. R.G. Moore, D.S. McMeekin, A.K. Brown, P. Disilvestro, M.C. Miller, W.J. Allard, and et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol. Oncol. 112 1 2009 Jan 40 46
12. R.G. Moore, M.C. Miller, P. Disilvestro, L.M. Landrum, W. Gajewski, J.J. Ball, and et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass Obstet Gynecol 118 2, Part 1 Aug 2011 280 288
13. R.G. Moore, D.M. Hawkins, M.C. Miller, L.M. Landrum, W. Gajewski, J.J. Ball, and et al. Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer Gynecol. Oncol. 135 3 2014 Dec 547 551
14. F.R. Ueland, C.P. DeSimone, L.G. Seamon, R.A. Miller, S. Goodrich, I. Podzielinski, and et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors Obstet. Gynecol. 117 6 2011 Jun 1289 1297
15. R.E. Bristow, A. Smith, Z. Zhang, D.W. Chan, G. Crutcher, E.T. Fung, and et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay Gynecol. Oncol. 128 2 2013 Feb 252 259
16. A.M. Chudecka-Glaz ROMA, an algorithm for ovarian cancer Clin. Chim. Acta 440 2015 Feb 2 143 151
17. H. Fujiwara, M. Suzuki, N. Takeshima, K. Takizawa, E. Kimura, T. Nakanishi, and et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women Tumour Biol. 36 2 2015 Feb 1045 1053
18. M.A. Karlsen, N. Sandhu, C. Hogdall, I.J. Christensen, L. Nedergaard, L. Lundvall, and et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass Gynecol. Oncol. 127 2 Nov 2012 379 383
19. B. Ortiz-Munoz, E. Aznar-Oroval, G.A. Garcia, P.A. Covisa, B.P. Perez, Y.M. Sanchez, and et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer Tumour Biol. 35 7 Jul 2014 7249 7258
20. S. Zhen, L.H. Bian, L.L. Chang, and X. Gao Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: a meta-analysis Mol Clin Oncol 2 4 Jul 2014 559 566
21. I. Jacobs, D. Oram, J. Fairbanks, J. Turner, C. Frost, and J.G. Grudzinskas A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer Br. J. Obstet. Gynaecol. 97 10 Oct 1990 922 929
22. P. Geomini, R. Kruitwagen, G.L. Bremer, J. Cnossen, and B.W. Mol The accuracy of risk scores in predicting ovarian malignancy: a systematic review Obstet. Gynecol. 113 2 Pt 1 Feb 2009 384 394
23. E.R. Myers, L.A. Bastian, L.J. Havrilesky, S.L. Kulasingam, M.S. Terplan, K.E. Cline, and et al. Management of adnexal mass Evid Rep Technol Assess (Full Rep) 130 Feb 2006 1 145
24. R.G. Moore, M. Jabre-Raughley, A.K. Brown, K.M. Robison, M.C. Miller, W.J. Allard, and et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass Am J Obstet Gynecol 2010 May 13
25. R.G. Moore, M.C. Miller, M.M. Steinhoff, S.J. Skates, K.H. Lu, G. Lambert-Messerlian, and et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders Am. J. Obstet. Gynecol. 206 4 Apr 2012 351 358
26. B. Nolen, L. Velikokhatnaya, A. Marrangoni, G.K. De, A. Lomakin, R.C. Bast Jr., and et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass Gynecol. Oncol. 117 3 Jun 2010 440 445
27. R.G. Moore, M.C. Miller, E.E. Eklund, K.H. Lu, R.C. Bast Jr., and G. Lambert-Messerlian Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age Am. J. Obstet. Gynecol. 206 4 Apr 2012 349 357